Pharmaceutical

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

PLEASANTON, Calif., Oct. 1, 2024 /PRNewswire/ -- At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy,…

3 months ago

Premise Health Digital Wellness Center Receives Accreditation from Accreditation Association for Ambulatory Health Care

Premise's Digital Wellness Center is the first virtual platform to receive accreditation from AAAHC BRENTWOOD, Tenn., Oct. 1, 2024 /PRNewswire/…

3 months ago

Scout Appoints Moisha Platto as Chief Executive Officer

DALLAS, Oct. 1, 2024 /PRNewswire/ -- Scout, a leader in services and technology for the biopharmaceutical industry, announces the appointment of…

3 months ago

EDETEK has appointed Dr. Shakthi Kumar, a leading industry executive, as its Chief Strategy and Business Officer

Dr. Shakthi Kumar, an industry leader in Life Sciences and Healthcare, has joined EDETEK's executive leadership team. Dr. Kumar will…

3 months ago

Axtria Recognized in 2024 Gartner® Hype Cycle™ for Life Science Commercial Operations

BERKELEY HEIGHTS, N.J., Oct. 1, 2024 /PRNewswire/ -- Axtria, a global leader in cloud software and data analytics for the…

3 months ago

NextPlat Announces Completion of Merger and Business Combination with Progressive Care Inc. as Company Focuses on Growth in Healthcare, Technology and Personal Wellness Markets

Progressive Care Stock to Cease Trading Today, October 1, 2024 COCONUT GROVE, Fla., Oct. 1, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:…

3 months ago

ClariMed Inc. Strengthens Leadership Team with Joe Dobkin as New VP of Services

CHADDS FORD, Pa., Oct. 1, 2024 /PRNewswire/ -- ClariMed, Inc., a global leader in human-centered medical device development and regulatory…

3 months ago

Astrix Accelerates Global Expansion with Enhanced Presence in Europe

Expanded European presence aims to meet increasing global demand from the life science industry. RED BANK, N.J., Oct. 1, 2024…

3 months ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)Patient Dosing Commenced 3Q Calendar Year…

3 months ago

Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy

- Phase 1 clinical trial for smoking cessation expected to dose first patient in 4Q 2024 - - The study…

3 months ago